Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 145

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 145
---
 | ​ |     287,722 | ​ |
| Interest expense, promissory note            | ​ | ​                                       |   -393,450 | ​ | ​ |    -410,317 | ​ |
| Loss on issuance of Series A Preferred Stock | ​ | ​                                       |          — | ​ | ​ | -11,088,997 | ​ |
| Total Other income (expense)                 | ​ | ​                                       |  3,503,578 | ​ | ​ |      97,408 | ​ |
| Loss before income taxes                     | ​ | ​                                       | -5,045,350 | ​ | ​ |  -8,481,338 | ​ |
| Income tax expense                           | ​ | ​                                       |          — | ​ | ​ |           — | ​ |
| Net loss                                     | ​ | $                                       | -5,045,350 | ​ | $ |  -8,481,338 | ​ |

Net Sales Net sales for the nine months ended September 30, 2024, were $4,386,640, composed of $2,086,180 of net sales from Prescription Medicines and net sales of $2,300,460 from Medical Devices. Net sales for the nine months ended September 30, 2023, were $6,186,638, composed of $3,416,444 of net sales from Prescription Medicines and net sales of $2,770,194 from Medical Devices. For the nine months ended September 30, 2024, gross billings to customers representing 10% or more of the Company’s total gross billings included three customers that represented approximately 28%, 25%, and 14% of total gross billings, respectively. Gross billings is a non-GAAP financial measure. For a reconciliation of net sales to gross billings, see the section titled “Reconciliation of Non-GAAP Financial Measures” below. For the nine months ended September 30, 2023, gross billings to customers representing 10% or more of the Company’s total gross billings included three customers that represented approximately 23%, 19%, and 17% of total gross billings. Gross billings is a non-GAAP financial measure. For a reconciliation of net sales to gross billings, see the section titled “Reconciliation of Non-GAAP Financial Measures” below. Prescription Medicines sales consist of sales of Stendra® in the U.S. for the treatment of male ED. St